Strategy


Deprecated: Function create_function() is deprecated in /home/litevax6/public_html/plugins/content/themlercontent/lib/Shortcodes.php on line 2035

It is our ambition to contribute to global health by the delivery of better adjuvants to increase the success of vaccination campaigns in developed and developing countries.

In pre-clinical studies with various types of antigens in large non-rodent species, our most advanced product gave significantly higher humoral responses than benchmark adjuvants after the first and second immunization.

Remarkably, a single injection with this new adjuvant gave similar (and sometimes even higher) antibody titers as two immunizations with benchmark adjuvant. So, it is a promising candidate for single-shot vaccines.

The single-shot approach offers enormous benefits related to costs of vaccination (goods, logistics and staffing), time-to-immunity, complexity of vaccination campaigns and non-adherence. In developing countries with poor infrastructure, these are critical success factors of campaigns and better adjuvants play a decisive role. Furthermore, in emergency situations avoiding the need for a booster offers tremendous advantages.

The adjuvant has been designed to facilitate incorporation into the manufacturing process of a wide range of vaccines. It is cheap, easy to manufacture, stable, filterable and ready-for-use in aqueous formulations. Pilot production has been completed successfully and manufacturing outline has been established.

Test material is available for research purposes under a material transfer agreement.

For research collaborations, test material or commercial licenses , please contact Luuk Hilgers at luuk.hilgers(at)litevax.com.